Big Pain Coming…

[anonymous]

Not good, 2025 hoping to be a very tough year…

https://www.cnbc.com/2025/02/04/merck-mrk-earnings-q4-2024.html

 

[anonymous]

Not good, 2025 hoping to be a very tough year…

https://www.cnbc.com/2025/02/04/merck-mrk-earnings-q4-2024.html

Maybe for once we will start being realistic about outlook. Merck assumes best case and seldom plan for worst case. Was it realistic to expect all untapped markets to embrace a vaccine that could go against certain cultural expectations and religious principals?

 

[anonymous]

I knew something was wrong when they served that thanksgiving lunch last year. turkey was hard as hell and the stuffing was stale.

 

[anonymous]

Maybe for once we will start being realistic about outlook. Merck assumes best case and seldom plan for worst case. Was it realistic to expect all untapped markets to embrace a vaccine that could go against certain cultural expectations and religious principals?

Yep, agree. We strung investors along with the Guardasil issue in China, paying for it now. Stock down 10 points, lot of market cap lost today. Dont kid yourself ET will be looking for ways to make that loss up.

 

[anonymous]

Yep, agree. We strung investors along with the Guardasil issue in China, paying for it now. Stock down 10 points, lot of market cap lost today. Dont kid yourself ET will be looking for ways to make that loss up.

Yep, its going to be a very tough year here

 

[anonymous]

Not good, 2025 hoping to be a very tough year…

https://www.cnbc.com/2025/02/04/merck-mrk-earnings-q4-2024.html

 

[anonymous]

What has happened to Merck? It used to have a solid R/D department, and so many good products that there were three separate sales forces. Did MRK execs forget what George Merck said, "the patients first and the profits will follow?" The stock used to split, now it tanks. Pathetic.

Not good, 2025 hoping to be a very tough year…

https://www.cnbc.com/2025/02/04/merck-mrk-earnings-q4-2024.html

 

[anonymous]

I’m not a believer that the new version of Keytruda will be the savior. Yes, injection is easier than infusion, but if each is equal in effectiveness, why would an insurance company shell out more money for our brand name? It reminds me of Schering—Claritin (little to no side effects) was going off patent so we came up with Clarinex (even fewer side effects). Complete bomb, why pay for fewer than ‘little to no side effects.’ That seemed to be a big impetus towards the merger with Merck. Wondering if history is repeating itself.